$NMDBF News
Last published 4y ago
- 4y agoNMDBFNeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis GrowsACCESS NewswirePartnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada OAKVILLE, ON / ACCESSWIRE / April 12, 2022 / NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF
- 4y agoNMDBFNeonMind Unveils Initial Treatment Offering at Specialty Mental Health Clinic in MississaugaACCESS NewswireTo Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic Licensing OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("Neon
- 4y agoNMDBFNeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal SubjectsACCESS NewswireData Further Validates Psilocybin as a Drug Candidate for Obesity and Supports Development of NeonMind's Drug Programs NEO-001 and NEO-002 OAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind
- 4y agoNMDBFNeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight LossACCESS NewswireOAKVILLE, ON / ACCESSWIRE / March 22, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to peo
- 4y agoNMDBFNeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate DevelopmentsACCESS NewswireCompleted concrete milestones in its strategy to become a leading psychedelic drug developer and specialty clinics operator. Developed clear drug development pathway for NEO-001, the industry's first psilocybin-based obesity treatment with near-term clin
- 4y agoNMDBFNeonMind and BioScript Solutions Announce Strategic Partnership Expanding NeonMind's Specialty Clinic Network for Interventional Psychiatry TreatmentsACCESS NewswireVANCOUVER, BC / ACCESSWIRE / March 3, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to peo
- 4y agoNMDBFNeonMind Appoints Emergency and Addiction Expert Dr. Dinesh Bhayana, as Site Medical Director of its Inaugural Specialty Mental Health ClinicACCESS NewswireVANCOUVER, BC / ACCESSWIRE / February 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to
- 4y agoNMDBFNeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioACCESS NewswireMississauga facility expected to begin treatment services in the Second Half of 2022 First location selected as part of a nationwide buildout of NeonMind-branded clinics offering interventional psychiatry treatments VANCOUVER, BC / ACCESSWIRE / Febru
- 4y agoNMDBFNeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory BoardACCESS NewswireDr. Bainbridge's Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics VANCOUVER, BC / ACCESSWIRE / January 13, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF)
- 4y agoNMDBFNeonMind to Present at H.C. Wainwright Bioconnect ConferenceACCESS NewswireVANCOUVER, BC / ACCESSWIRE / January 6, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company, announced today that Robert Tessarolo, President and Chief Exec
- 4y agoNMDBFNeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual ConferenceACCESS NewswireVANCOUVER, BC / ACCESSWIRE / December 2, 2021 / NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for t
- 4y agoNMDBFNeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001ACCESS NewswireFDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss Company plans to file an IND application for a Phase 1/2 clinical study anticipated
- 4y agoNMDBFNeonMind to Participate in Panel Discussion at Lift & Co. Expo's Psychedelics Business Summit on November 19, 2021ACCESS NewswireVANCOUVER, BC / ACCESSWIRE / November 17, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company, is pleased to announce that President and CEO, Rob Tessarolo,
- 5y agoNMDBFNeonMind and SRx Health Solutions Announce Strategic Alliance to Establish Specialty Mental Health Clinics for Interventional Psychiatry TreatmentsACCESS NewswireVANCOUVER, BC / ACCESSWIRE / November 8, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company, today announced a strategic alliance with SRx Health Solutions
- 5y agoNMDBFNeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia MagazineACCESS NewswireAnnounces Participation in Microdose's Wonderland: Miami on November 8-9, 2021 VANCOUVER, BC / ACCESSWIRE / November 5, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind"), an integrated drug development and wellness company,
- 5y agoAWKNFBETRFBMBIFCYBN+16KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand ViewingPR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
- 5y agoAWKNFBETRFBMBIFCYBN+13KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14thPR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional inves
- 5y agoNMDBFNeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14thPR NewswireVANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -- NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA: 6UF) ("NeonMind" or the "Company"), based in Vancouver, focused on the potential therapeutic uses of psilocybin for treating obesity and weight manage
- 5y agoNMDBFNeonMind Advances Strategy for Specialty Clinic LaunchACCESS NewswireCompany expects to launch first specialty clinic locations by early 2022 NeonMind-branded specialty mental health clinics to bring innovative interventional psychiatry treatments to underserved populations in Canada VANCOUVER, BC / ACCESSWIRE / Septemb
- 5y agoNMDBFNeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.ACCESS NewswireCompany Continues to Expand Its Scientific Expertise with Noted Expert in Utilizing Ketamine for Treatment Resistant Depression VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or
- 5y agoNMDBFNeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory BoardACCESS NewswireCompany Broadens Scientific Expertise with Addition of Mental Health Expert in Setting Up and Managing Interventional Psychiatric Clinics VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FSE:6UF) ("Neon
- 5y agoNMDBFNeonMind Announces Divestiture of Consumer Related and Other Non-Core AssetsACCESS NewswireReflects Strategic Focus on Psychedelic Treatments with Major Milestones in 2021 VANCOUVER, BC / ACCESSWIRE / September 13, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind", the "Company"), announced it has completed the sal
- 5y agoNMDBFNeonMind to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceACCESS NewswireVANCOUVER, BC / ACCESSWIRE / September 8, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind''or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for tre
- 5y agoNMDBFNeonMind Announces DTC EligibilityACCESS NewswireVANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for trea
- 5y agoNMDBFNeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend'ACCESS NewswireVANCOUVER, BC / ACCESSWIRE / August 17, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for trea
- 5y agoNMDBFNeonMind Announces Corporate Update and Strategic Reorganization of its Pharmaceutical DivisionACCESS NewswireDesigned to Accelerate Execution of Integrated Drug Development Plan for NEO-001 to Treat Obesity Establishes R&D Advisory Board, Appoints Philippe Martin as Chairman Expands Regulatory Capabilities in Preparation for Proof-of-Concept Study VANCOUVE
- 5y agoNMDBFDr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory BoardACCESS NewswireVANCOUVER, BC / ACCESSWIRE / July 28, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treati
- 5y agoNMDBFNeonMind Provides Integrated Drug Development Plan Update for NEO-001 to Treat ObesityACCESS NewswireTarget Product Profile and Clinical Phase 1/2 Study Aim To Address Deficiencies In Chronic Weight Management Pre-IND Meeting in the U.S. and Pre-CTA Consultation Meeting in Canada Targeted for 4Q2021 Initiation of Phase 1/2 Clinical Proof of Concept S
- 5y agoNMDBFNeonMind Announces Launch of Functional Mushroom Coffees as Dietary Supplements in the USACCESS NewswireVANCOUVER, BC / ACCESSWIRE / June 29, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), a psychedelic drug development company, is pleased to announce that it has launched its NeonMind branded functional mu
- 5y agoARHHAVCRFBABYFCLXPF+9Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingGlobeNewswireNEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased
- 5y agoNMDBFNeonMind to Webcast Live at Life Sciences Investor Forum June 24thGlobeNewswireVANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) -- NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA: 6UF) ("NeonMind" or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of
- 5y agoARHHAVCRFBABYFCLXPF+9Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021GlobeNewswireNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will s